KRAS and neoplasm: Contrast agents have been used previously in the Kras+/LSL-G12D mouse model to better differentiate tumours from the surrounding vasculature (Lalwani et al., 2013), and detection of smaller tumours has been enhanced using bioluminescence and fluorescence biomarkers (Rodriguez et al., 2014).